Market Place
Sourcing Support
Urovant Announces Collaboration with Holly Robinson Peete for Overactive Bladder
19 Jan 2023 //
BUSINESSWIRE
Urovant launches overactive bladder awareness campaign
17 Nov 2022 //
FIERCEPHARMA
Urovant Sciences Announces Partnership with Thinx Inc.
14 Nov 2022 //
BUSINESSWIRE
Urovant Announces Publication of Pharmacokinetic Data on GEMTESA
27 Oct 2022 //
BUSINESSWIRE
The Impact of Urinary Incontinence Related to Overactive Bladder
13 Jul 2022 //
BUSINESSWIRE
Urovant and Pierre Fabre Sign Excl. License Agreement to Commercialize Vibegron
06 Jul 2022 //
BUSINESSWIRE
Urovant Sciences Presents New Data from EMPOWUR Study at AUA
15 May 2022 //
BUSINESSWIRE
Urovant Sciences Presents Interim Data from Phase 2a Study of URO-902
13 May 2022 //
BUSINESSWIRE
Urovant to Publish EMPOWUR Trial Subgroup Analysis in d/w Overactive Bladder
19 Apr 2022 //
BUSINESSWIRE
Urovant Sciences to Present Interim Data from Phase 2a Study of URO-902
13 Apr 2022 //
BUSINESSWIRE
CORRECTING and REPLACING Urovant Sciences Appoints Sef Kurstjens as EVP & CMO
04 Apr 2022 //
BUSINESSWIRE
Urovant Sciences Publishes Review of Efficacy and Safety Data for GEMTESA 75 mg
22 Mar 2022 //
BUSINESSWIRE
Urovant Shows Positive Topline Results of Phase 2a Trial of URO-902
07 Mar 2022 //
BUSINESSWIRE
Urovant to publish in Advances in Therapy of Improvement by GEMTESA in OAB
20 Dec 2021 //
BUSINESSWIRE
Urovant Makes Appointments to Drive Future Growth & Geographic Expansion
18 Oct 2021 //
BUSINESSWIRE
Urovant Sciences Presents Positive Ambulatory Blood Pressure Data of GEMTESA
13 Sep 2021 //
BUSINESSWIRE
Urovant to Present New Blood Pressure Data in Patients Dosed With GEMTESA 75 mg
03 Sep 2021 //
BUSINESSWIRE
Urovant to Present New Blood Pressure Data in Patients Dosed With GEMTESA 75 mg
03 Sep 2021 //
BUSINESSWIRE
Urovant Sciences Appoints Betzy Estrada as Executive Vice President
12 Aug 2021 //
BUSINESSWIRE
Urovant Sciences Named One of the 2021 Best Places to Work in Orange County
07 Jul 2021 //
BUSINESSWIRE
Urovant Sciences and Sunovion Launch Primary Care Co-Promotion of GEMTESA
29 Jun 2021 //
BUSINESSWIRE
Urovant Announces Publication of Positive Long-Term Safety & Efficacy Data
15 Apr 2021 //
BUSINESSWIRE
Urovant Sciences Announces U.S. Commercial Launch of GEMTESA®
13 Apr 2021 //
GLOBNEWSWIRE
Urovant Announces Progression of URO-902 Phase 2a Trial Following Positive
11 Feb 2021 //
BIOSPACE
Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following
11 Feb 2021 //
BUSINESSWIRE
Vivek Ramaswamy`s `vant` brainchildren keep bearing fruit with Urovant`s FDA
24 Dec 2020 //
ENDPTS
Vivek Ramaswamy`s `vant` brainchildren keep bearing fruit with Urovant`s FDA
24 Dec 2020 //
ENDPTS
FDA clears Sumitovant`s Gemtesa for patients with overactive bladder
24 Dec 2020 //
GLOBENEWSWIRE
Urovant`s lead drug disappoints in mid-stage study first big FDA decision looms
26 Nov 2020 //
ENDPTS
Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron
24 Nov 2020 //
BUSINESSWIRE
Urovant Sciences Announces Topline Data from Phase 2a Study of VibegroN
24 Nov 2020 //
BUSINESSWIRE
Urovant gets snapped up by Sumitovant Biopharma
13 Nov 2020 //
FIERCEBIOTECH
Japanese drugmaker takes full control of a Roivant biotech
13 Nov 2020 //
BIOPHARMADIVE
Urovant Sciences Announces Co-Promotion Agreement for Vibegron SunovionPharma
08 Oct 2020 //
PRESS RELEASE
Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion
07 Oct 2020 //
BUSINESSWIRE
As Urovant preps vibegron launch, it’s all systems go on R&D
15 Aug 2020 //
FIERCE PHARMA
As Urovant preps vibegron launch, it’s all systems go on R&D
13 Aug 2020 //
FIERCE BIOTECH
Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals
18 Jun 2020 //
BUSINESS WIRE
Urovant Sciences Appoints James Hindman to Board of Directors
26 May 2020 //
BUSINESSWIRE
Urovant hires Astellas alum Robinson as CEO—Chutes & Ladders
27 Mar 2020 //
FIERCE BIOTECH
FDA sets Dec. PDUFA date for Urovant rival to Astellas drug
06 Mar 2020 //
FIERCE BIOTECH
Urovant Sciences Announces U.S. FDA Acceptance of NDA for Vibegron
05 Mar 2020 //
BIOSPACE
Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial
02 Mar 2020 //
BUSINESSWIRE
Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results
02 Mar 2020 //
BUSINESSWIRE
Urovant Sciences Announces Pub of Results from Ph1 Trials Evaluating URO-902
05 Feb 2020 //
BUSINESSWIRE
Urovant inks $300M loan agreement with Sumitomo Pharma
01 Jan 2020 //
BIOSPECTRUMASIA
Urovant Sciences Announces Submission of New Drug Application for Vibegron
30 Dec 2019 //
BUSINESSWIRE
Urovant Sciences Initiates Part 2 of Phase 3 COURAGE Study of Vibegron
21 Oct 2019 //
PR NEWSWIRE
Urovant Reports Positive Long-Term Data from the Double-Blind Extension
24 Sep 2019 //
BUSINESSWIRE
BeiGene, Sumitomo-Roivant, Roche-JHL and more
13 Sep 2019 //
FIERCE PHARMA
Roivant lines up $3B upfront in Sumitomo Dainippon deal
06 Sep 2019 //
FIERCEBIOTECH
Urovant ramps up spending on Codexis ingredient ahead of commercial production
13 Aug 2019 //
IN-PHARMATECHNOLOGIST
Urovant Sciences Initiates Phase 3 Clinical Program with Vibegron
27 Mar 2019 //
BUSINESSWIRE
Urovant Sciences Initiates Pt Enrollment in Ph2a Clinical Trial for Vibegron
03 Jan 2019 //
BUSINESSWIRE
Andreas Halvorsen Discloses Stake In Urovant Sciences
13 Oct 2018 //
FORBES
Urovant Sciences Ltd. Announces Pricing of Initial Public Offering
26 Sep 2018 //
PR NEWSWIRE
Overactive bladder biotech Urovant Sciences sets terms for $150 million IPO
17 Sep 2018 //
NASDAQ
Urovant starts pursuit of Astellas’ incontinence drug Myrbetriq
28 Mar 2018 //
FIERCE BIOTECH
